Back to news

Dermata Highlights Additional Results and Photos from Cosmetic Study Evaluating Its Tome Foundational Treatment

ACCESSWIRE•17/11/2026•08:30 ET
0

Key Highlights

  • ➤Over 1,000 Tome Foundational Treatment orders received since launch
  • ➤77% of 31 participants noticed skin improvements after four weeks
  • ➤74% said Tome felt like a professional skincare treatment
  • ➤No treatment-related adverse events reported in the 31-participant study

Expert Statements

Gerry Proehl, Chairman, President, and Chief Executive Officer of Dermata

“We believe these additional findings and participant photos further reinforce our confidence in Tome Foundational Treatment and the opportunity to establish Tome as a premium skincare brand in the skincare and beauty market.”

Gerry Proehl, Chairman, President, and Chief Executive Officer of Dermata

“As a newly commercialized skincare brand, we believe demonstrating the visible benefits of our Tome products in a clinical setting is critical to building consumer confidence, establishing credibility, and driving consumer adoption.”

Gerry Proehl, Chairman, President, and Chief Executive Officer of Dermata

“We believe the ability to pair participant assessments with before-and-after photography gives us compelling tools to communicate the benefits of Tome to consumers and skincare professionals.”

Gerry Proehl, Chairman, President, and Chief Executive Officer of Dermata

“We are excited that the results from the clinical study appear to align with the real-world customer feedback we've received thus far.”

Gerry Proehl, Chairman, President, and Chief Executive Officer of Dermata

“We are also encouraged with consumer interest in the Tome Foundational Treatment, having received over 1,000 orders since launch.”

SAN DIEGO, CA / ACCESS Newswire / November 17, 2026 / Dermata Therapeutics, Inc. (Nasdaq:DRMA) ("Dermata," or the "Company"), a science-driven leader in dermatologic solutions, today highlighted additional results and photos from its recently completed cosmetic clinical study evaluating Tome Foundational Treatment, the Company's recently launched once-weekly skin renewal treatment. Building on the positive topline results previously announced by the Company, the additional findings provide further insight into the Tome Foundational Treatment, including its ability to improve skin texture, tone, dark spots, smoothness, and overall appearance.

"We believe these additional findings and participant photos further reinforce our confidence in Tome Foundational Treatment and the opportunity to establish Tome as a premium skincare brand in the skincare and beauty market," said Gerry Proehl, Chairman, President, and Chief Executive Officer of Dermata. "As a newly commercialized skincare brand, we believe demonstrating the visible benefits of our Tome products in a clinical setting is critical to building consumer confidence, establishing credibility, and driving consumer adoption. We believe the ability to pair participant assessments with before-and-after photography gives us compelling tools to communicate the benefits of Tome to consumers and skincare professionals," continued Mr. Proehl. "We are excited that the results from the clinical study appear to align with the real-world customer feedback we've received thus far. We are also encouraged with consumer interest in the Tome Foundational Treatment, having received over 1,000 orders since launch," concluded Mr. Proehl.

Get started

Create a free account to read the full story.

Sign Up

Already have an account? Log in